Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-04-09
2010-10-26
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S333000, C530S334000, C530S338000, C530S350000, C530S408000
Reexamination Certificate
active
07820162
ABSTRACT:
The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.
REFERENCES:
patent: 3941763 (1976-03-01), Sarantakis
patent: 4695623 (1987-09-01), Stabinsky
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4831119 (1989-05-01), Nordfang et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 5077204 (1991-12-01), Brake et al.
patent: 5093246 (1992-03-01), Cech et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5162220 (1992-11-01), Oshima et al.
patent: 5175096 (1992-12-01), Höök et al.
patent: 5189015 (1993-02-01), Höök et al.
patent: 5234830 (1993-08-01), Oshima et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5482858 (1996-01-01), Huston et al.
patent: 5579277 (1996-11-01), Kelly et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5591573 (1997-01-01), Whalen et al.
patent: 5605689 (1997-02-01), Ammann
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648240 (1997-07-01), Hook et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5869046 (1999-02-01), Presta et al.
patent: 5885821 (1999-03-01), Magota et al.
patent: 5910573 (1999-06-01), Plückthun et al.
patent: 6013263 (2000-01-01), Barney et al.
patent: 6015881 (2000-01-01), Kang et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6060065 (2000-05-01), Barney et al.
patent: 6060613 (2000-05-01), Hattori et al.
patent: 6068973 (2000-05-01), Barney et al.
patent: 6086875 (2000-07-01), Blumberg et al.
patent: 6093799 (2000-07-01), Li et al.
patent: 6184344 (2001-02-01), Kent et al.
patent: 6228983 (2001-05-01), Barney et al.
patent: 6281331 (2001-08-01), Kang et al.
patent: 6310180 (2001-10-01), Tam
patent: 6310183 (2001-10-01), Johannessen et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6326468 (2001-12-01), Canne et al.
patent: 6329176 (2001-12-01), Wöldike et al.
patent: 6469136 (2002-10-01), Bray et al.
patent: 6475491 (2002-11-01), Johnson et al.
patent: 6485726 (2002-11-01), Blumberg et al.
patent: 6518013 (2003-02-01), Barney et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 7084109 (2006-08-01), Dennis et al.
patent: 7348004 (2008-03-01), Peters et al.
patent: 7381408 (2008-06-01), Mezo et al.
patent: 7385032 (2008-06-01), Tschopp et al.
patent: 7404956 (2008-07-01), Peters et al.
patent: 2002/0081664 (2002-06-01), Lo et al.
patent: 2002/0106374 (2002-08-01), Olson et al.
patent: 2003/0119727 (2003-06-01), Dennis et al.
patent: 2003/0180287 (2003-09-01), Gambotz et al.
patent: 2003/0235536 (2003-12-01), Blumberg et al.
patent: 2004/0077022 (2004-04-01), Feige et al.
patent: 2004/0110929 (2004-06-01), Bjorn et al.
patent: 2005/0027109 (2005-02-01), Mezo et al.
patent: 2005/0037941 (2005-02-01), Munoz et al.
patent: 2005/0037947 (2005-02-01), Bitonti et al.
patent: 2005/0147618 (2005-07-01), Riviera et al.
patent: 2005/0281829 (2005-12-01), Hehir et al.
patent: 2007/0172928 (2007-07-01), Peters et al.
patent: 0 325 262 (1989-07-01), None
patent: 0 464 533 (1992-01-01), None
patent: 0 589 577 (1997-02-01), None
patent: 2 641 468 (1990-07-01), None
patent: WO 88/09810 (1988-12-01), None
patent: WO 89/10134 (1989-02-01), None
patent: WO 90/11364 (1990-10-01), None
patent: WO 92/10209 (1992-06-01), None
patent: WO 93/11162 (1993-06-01), None
patent: WO 96/22024 (1996-07-01), None
patent: WO 00/06605 (2000-02-01), None
patent: WO 00/18881 (2000-04-01), None
patent: WO 01/02439 (2001-01-01), None
patent: WO 01/02440 (2001-01-01), None
patent: WO 01/03737 (2001-01-01), None
patent: WO 01/36637 (2001-05-01), None
patent: WO 01/58935 (2001-08-01), None
patent: WO 01/83526 (2001-11-01), None
patent: WO 01/91780 (2001-12-01), None
patent: WO 02/18417 (2002-03-01), None
patent: WO 02/46208 (2002-06-01), None
patent: WO 02/089828 (2002-11-01), None
patent: WO 03/077834 (2003-09-01), None
patent: WO 2004/003176 (2004-01-01), None
patent: WO 2004/006962 (2004-01-01), None
patent: WO 2004/101740 (2004-11-01), None
patent: WO 2005/001025 (2005-01-01), None
patent: WO 2005/051289 (2005-06-01), None
Armour, K.L., et al., “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities,”Eur. J. Immunol.29:2613-2624, Wiley (1999).
Aruffo, A., et al., “CD44 is the principal cell surface receptor for hyaluronate,”Cell61:1303-1313, Cell Press (1990).
Ashkenazi, A., et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,”Proc. Natl. Acad. Sci. U.S.A.88:10535-10539, National Academy of Science (1991).
Bahlmann, F.H., et al., “Erythropoietin: is it more than correcting anaemia?,”Nephrol. Dial. Transplant.19:20-22, Oxford University Press (2004).
Barré-Sinoussi, F., et al., “Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS),”Science220:868-871, Association for the Advancement of Science (1983).
Baru M. et al., “Liposome-encapsulated DNA mediated gene transfer and synthesis of human factor IX in mice,”Gene161: 143-150,Elsevier Science B. V.(1995).
Bennett, B.D., et al., “Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors,”J. Biol. Chem.266:23060-230607, American Society for Biochemistry and Molecular Biology (1991).
Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1Fragments,”Science229:81-83, Association for the Advancement of Science (1985).
Botti, P., et al., “Cyclic Peptides from Linear Unprotected Peptide Precursors through Thiazolidine Formation,”J. Am. Chem. Soc.118:10018-10024, American Chemical Society (1996).
Broze, G.J., Jr. and Majerus, P.W., et al., “Purification and Properties of Human Coagulation Factor VII,”J. Biol. Chem.255:1242-1247, American Society for Biochemistry and Molecular Biology (1980).
Burmeister, W.P., et al., “Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor,”Nature371:323-324, Nature Publishing Group (1994).
Byrn, R.A., et al., “Biological properties of a CD4 immunoadhesin,”Nature344:667-670, Nature Publishing Group (1990).
Capon, D.J., et al., “Designing CD4 immunoadhesins for AIDS therapy,”Nature337:525-531, Nature Publishing Group (1989).
Carter, D.C. and Ho, J.X., “Structure of Serum Albumin,”Adv. Prot. Chem.45:153-203, Academic Press (1994).
Chalupny, N.J., et al., “T-cell activation molecule 4-1BB binds to extracellular matrix proteins,”Proc. Natl. Acad. Sci. U.S.A.89:10360-10364, National Academy of Science (1992).
Chan, D.C. and Kim, P.S., “HIV Entry and Its inhibition,”Cell93:681-684, Cell Press (1998).
Clerc, F.F., et al., “Primary structure control of recombinant proteins using high-performance liquid chromatography, mass spectrometry and microsequencing,”J. Chromatogr. B Biomed. Appl.662:245-259, Elsevier (1994).
Cohen, A.J. and Kessler, C.M., “Acquired Inhibitors,”Baillieres Clin. Hematol.9:331-354, Bailliere Tindall (1996).
Dagleish, A.G., et al., “The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus,”Nature312:763-767, Nature Publishing Group (1984).
Dargaud Y. and Negrier C., “Heamophilia therapies,” Expert Opinions on Biological Therapy, 7(5): 651-663, Ashley Publications Ltd. (2007).
Davis, L.E., et al., “Preparation and characterization of antibodies with specificity for the amino-terminal tetrapeptide sequence of the platelet-derived connective tissue activating peptide-III,”Biochem.
Mezo Adam R.
Peters Robert T.
Kam Chih-Min
Sterne Kessler Goldstein & Fox P.L.L.C.
Syntonix Pharmaceuticals, Inc.
LandOfFree
Methods for chemically synthesizing immunoglobulin chimeric... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for chemically synthesizing immunoglobulin chimeric..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for chemically synthesizing immunoglobulin chimeric... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4154581